Marijuana, Hemp, and CBD: Navigating the Complex Federal, State & Local Landscapes (2021 Update)
Created on April 20, 2021
Since the federal legalization of hemp in December 2018, we have seen explosive growth in hemp production, specifically the production of hemp-derived CBD products (e.g., food, beverages, topicals, dietary supplements, cosmetics, smokable hemp, vaping products, and more). However, the U.S. Food and Drug Administration (FDA), the Federal Trade Commission (FTC), states and localities, and the plaintiff's attorneys have not been shy about going after products in this space. In this exciting and interactive session, Jonathan Havens, a former FDA regulator, and Capitol Hill staffer, will discuss the current CBD policy and regulatory landscapes and how they might change.
- Identify how the FDA, FTC, and other federal and state government agencies are regulating hemp/hemp-derived CBD products
- Examine the FDA's approach to CBD and understand what action, if any, that the FDA may take near term and long term
- Comprehend how federal and state legislative efforts could impact FDA's role in the space
Recognize the importance of CBD sourcing, labeling, and testing
Differentiate between hemp and marijuana, and ensure compliance with federal and state controlled substances laws
Understand how regulators will approach new product trends (e.g., Delta-8 THC)
Please note that this pre-recorded webcast is 78 minutes.
Gain access to this course, plus unlimited access to 1,500+ courses, with an Unlimited Subscription.Explore Lawline Subscriptions